Kelly, Louise; Brown, Christopher; Michalik, Daniel; Hawkes, Cheryl A; Aldea, Roxana; Agarwal, Nivedita; Salib, Rami; Alzetani, Aiman; Ethell, Douglas W; Counts, Scott E; de Leon, Mony; Fossati, Silvia; Koronyo-Hamaoui, Maya; Piazza, Fabrizio; Rich, Steven A; Wolters, Frank J; Snyder, Heather; Ismail, Ozama; Elahi, Fanny; Proulx, Steven T; ... (2024). Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA), updates in 2022-2023. Cerebrovascular disease and the failure of elimination of Amyloid-β from the brain and retina with age and Alzheimer's disease: Opportunities for therapy. Alzheimer's & dementia : the journal of the Alzheimer's Association, 20(2), pp. 1421-1435. 10.1002/alz.13512
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Alzheimer_s_Dementia_-_2023_-_Kelly_-_Clearance_of_interstitial_fluid_ISF_and_CSF_CLIC_group_part_of_Vascular.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (843kB) | Request a copy |
This editorial summarizes advances from the Clearance of Interstitial Fluid and Cerebrospinal Fluid (CLIC) group, within the Vascular Professional Interest Area (PIA) of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART). The overarching objectives of the CLIC group are to: (1) understand the age-related physiology changes that underlie impaired clearance of interstitial fluid (ISF) and cerebrospinal fluid (CSF) (CLIC); (2) understand the cellular and molecular mechanisms underlying intramural periarterial drainage (IPAD) in the brain; (3) establish novel diagnostic tests for Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), retinal amyloid vasculopathy, amyloid-related imaging abnormalities (ARIA) of spontaneous and iatrogenic CAA-related inflammation (CAA-ri), and vasomotion; and (4) establish novel therapies that facilitate IPAD to eliminate amyloid β (Aβ) from the aging brain and retina, to prevent or reduce AD and CAA pathology and ARIA side events associated with AD immunotherapy.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Theodor Kocher Institute |
UniBE Contributor: |
Proulx, Steven Thomas |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1552-5279 |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
30 Oct 2023 10:01 |
Last Modified: |
22 Feb 2024 00:13 |
Publisher DOI: |
10.1002/alz.13512 |
PubMed ID: |
37897797 |
Uncontrolled Keywords: |
ARIA IPAD ISTAART amyloid cerebrospinal fluid clearance interstitial fluid |
BORIS DOI: |
10.48350/188287 |
URI: |
https://boris.unibe.ch/id/eprint/188287 |
Actions (login required)
 |
Edit item |